Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLivermore Regulatory News (LIV)

Share Price Information for Livermore (LIV)

Share Price is delayed by 15 minutes
Get Live Data
44.60    0.00 (0.00%)
Bid:
42.40
Ask:
47.00
Spread: 4.60 (10.849%)
Market Cap: £73.75m
LIV Live PriceLast checked at - London Stock Exchange

Intraday Livermore Share Chart

COVID-19 update

9 Apr 2020 07:00

RNS Number : 2823J
Livermore Investments Group Limited
09 April 2020
 

9 April 2020

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

LIVERMORE INVESTMENTS GROUP LIMITED

 

("Livermore" or the "Company")

 

COVID-19 Update

 

 

Livermore today provides a statement on the impact of COVID-19.

The Company continues to monitor the COVID-19 pandemic situation closely, with a focus on the impact on the Company's CLO and US senior secured loan portfolios. The spread of the virus, government policy responses and changing demand patterns are expected to have a negative impact on the operations and earnings of some of the borrowers in the CLO portfolio. The Company has been in close contact with managers of its individual CLO positions and is tracking the level of rating downgrades of underlying loans to CCC+/Caa rating and a worsening default outlook. A significant concentration of CCC+/Caa rated loans can turn off the distributions to the equity and lower mezzanine tranches of CLOs and would result in significant drop in the market values of those CLO portfolio constituents. At this early stage it is not possible to quantify the impact, but further updates will be provided as more information becomes available. The full extent of the impact will depend on the length and severity of the crisis and is expected to vary widely between sectors and companies.

The Company has been positioned very conservatively for several months with high liquidity and cash reserves (in excess of USD 60m as of 31 March 2020) and a CLO portfolio that consists largely of CLOs with long reinvestment periods, which should benefit somewhat from the volatility in the market. The Company has no debt.

Looking forward, the Company believes it is very well positioned with its large cash reserves to capitalize on a recovery in trade in the CLO markets when there is more clarity on positive developments in the US economy and the US credit markets.

 

 

Enquiries:

 

Livermore Investments Group Limited

 +41 43 344 3200

Gaurav Suri

 

 

Nominated Broker and Adviser

Arden Partners

Richard Johnson

 

+44 207 614 5917

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTDVLFBBZLBBBX
Date   Source Headline
27th May 20267:00 amRNSFinal Results
18th Feb 20267:45 amRNSAppointment of Directors
13th Nov 20251:00 pmRNSMajor shareholding notification
22nd Oct 20257:00 amRNSAppointment of Non-Executive Director
26th Sep 20257:00 amRNSInterim Results
26th Aug 20256:00 pmRNSResults of AGM and Board Change
1st Jul 20257:00 amRNSPosting of Accounts and Notice of AGM
23rd Jun 20254:01 pmRNSInterim Dividend Exchange Rate
23rd May 20253:09 pmRNSInterim Dividend
23rd May 20257:00 amRNSFinal Results
2nd Jan 20257:00 amRNSDirectorate Change
8th Nov 20247:00 amRNSInterim dividend exchange rate
30th Sep 20247:00 amRNSInterim Dividend
26th Sep 20247:00 amRNSInterim Results
27th Aug 20242:05 pmRNSResult of AGM
28th Jun 202411:00 amRNSPosting of Accounts and Notice of AGM
23rd May 20247:00 amRNSFinal Results
18th Dec 20234:23 pmRNSInterim dividend exchange rate
6th Dec 20234:10 pmRNSFurther re Interim Dividend
21st Nov 20237:00 amRNSInterim Dividend
29th Sep 20237:00 amRNSInterim Results
29th Aug 202311:30 amRNSResult of AGM
3rd Aug 20237:55 amRNSCorrection of AGM date
29th Jun 202311:00 amRNSPosting of Report and Accounts and Notice of AGM
22nd May 20237:05 amRNSDirector transfer of shares
22nd May 20237:00 amRNSFinal Results
24th Jan 20231:07 pmRNSChange of Adviser
30th Sep 20227:00 amRNSInterim Results
23rd Aug 202212:01 pmRNSResult of Annual General Meeting
18th Jul 202210:58 amRNSCompletion of Nominated Adviser Due Diligence
30th Jun 202210:14 amRNSPosting of Report and Accounts and Notice of AGM
30th May 20227:00 amRNSFinal Results
27th May 20222:36 pmRNSAIM Rule 17 – Schedule 2(g) update
27th Apr 202211:00 amRNSAppointment of Nominated Adviser
26th Apr 202210:27 amRNSAIM Rule 17 - historic disclosure
5th Jan 20227:00 amRNSDividend Declaration
12th Oct 20217:00 amRNSDirector/PDMR Shareholding
29th Sep 20214:30 pmRNSInterim Results
25th Aug 20212:02 pmRNSResult of Annual General Meeting
30th Jun 20217:00 amRNSAnnual Report and Notice of AGM
26th May 20217:00 amRNSFinal Results
10th May 20214:41 pmRNSSecond Price Monitoring Extn
10th May 20214:35 pmRNSPrice Monitoring Extension
8th Mar 20212:52 pmRNSInterim Dividend Declaration
18th Feb 20219:00 amRNSDirector dealing, Share buyback and TVR
28th Sep 20209:30 amRNSINTERIM RESULTS FOR SIX MONTHS ENDED 30 JUNE 2020
25th Aug 202011:37 amRNSResult of AGM
19th Aug 20207:00 amRNSAGM - change of location
8th Jul 20207:00 amRNSAGM - revised Forms of Proxy and Direction
26th Jun 202011:36 amRNSPosting of Report and Accounts and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.